Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

9. Mai 2014 aktualisiert von: Molecular Research Center, Inc.

A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis

This study will treat moderate to severe rheumatoid arthritis with MRC375 (either 75 mg 3 times a day, 150 mg 3 times a day or placebo 3 times a day)in patients 18 years of age or older that can be currently on low doses of methotrexate or can stop treatment of current RA medications to enter the study. Safety of MRC375 will also be evaluated. There are up to 8 clinic visits over 24 weeks.

Studienübersicht

Status

Unbekannt

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a double-blind, randomized, placebo-controlled study to assess the safety and efficacy of MRC375 at 75 mg or 150 mg with matching placebo (taken tid with meal or light snack) in patients with moderate to severe RA. Patients will be randomized to one of the following study arms for 24 weeks:

  • Treatment 1, Placebo: 2 tablets taken tid
  • Treatment 2, MRC375: 1 tablet of 75 mg tetracycline HCL plus 1 matching placebo tablet taken tid. Total daily dose = 225 mg.
  • Treatment 3, MRC375: 2 tablets of 75 mg tetracycline HCL taken tid. Total daily dose = 450 mg.

Study medication should be taken within 30 minutes of a meal or light snack (either before or after).

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

300

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Alabama
      • Mobile, Alabama, Vereinigte Staaten, 36608
        • Mobile Diagnostic Center Rheumatology
    • California
      • Long Beach, California, Vereinigte Staaten, 90806
        • Valerius Medical Group
      • Los Alamitos, California, Vereinigte Staaten, 90720
        • Trial Concierge/Pacific Clinical Studies
      • Los Angeles, California, Vereinigte Staaten, 90036
        • Axis Clinical Trials
    • Florida
      • Edgewater, Florida, Vereinigte Staaten, 32132
        • Riverside Clinical Research
      • Miami, Florida, Vereinigte Staaten, 33156
        • Global Clinical Professionals
      • Palm Harbor, Florida, Vereinigte Staaten, 34684
        • The Arthritis Center
      • Summerfield, Florida, Vereinigte Staaten, 34491
        • Lakeview Medical Research
    • Kansas
      • Lenexa, Kansas, Vereinigte Staaten, 66219
        • Analan Clinical Research
    • Kentucky
      • Owensboro, Kentucky, Vereinigte Staaten, 42303
        • Trial Concierge
    • Nebraska
      • Omaha, Nebraska, Vereinigte Staaten, 68114
        • Quality Clinical Research, Inc.
    • Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89123
        • Advanced Biomedical Research of America
      • Reno, Nevada, Vereinigte Staaten, 89502
        • Arthritis Center of Reno
    • North Carolina
      • Salisbury, North Carolina, Vereinigte Staaten, 28144
        • PMG Research of Salisbury
    • Ohio
      • Dayton, Ohio, Vereinigte Staaten, 45439
        • Providence Health Partners
      • Middleburg Heights, Ohio, Vereinigte Staaten, 44130
        • Paramount Medical Research & Consulting, LLC
    • Virginia
      • Williamsburg, Virginia, Vereinigte Staaten, 23185
        • The Center for Excellence in Aging and Geriatric Health
    • Washington
      • Kennewick, Washington, Vereinigte Staaten, 99336
        • Apex Clinical Research
      • Olympia, Washington, Vereinigte Staaten, 98502
        • South Puget Sound Clinical Research Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Is 18 years of age
  2. Is diagnosed with moderate to severe adult onset RA > = 6 months duration, as defined by the 1987 ACR classification criteria

  3. Has moderate to severe RA as defined by:

    • ≥4 tender joints/painful (28 joint count) at screening
    • ≥4 swollen joints (28 joint count) at screening
  4. Has a Health Assessment Questionnaire (HAQ) of >0
  5. Has a physician global assessment (Likert scale) of >0
  6. Has a patient global assessment of pain (Likert scale) of >0
  7. Has a patient assessment of pain (Likert scale) of >0

  8. Has stable doses of the following allowable medications during the study, if applicable:

    • Stable dose of NSAIDs or other analgesics for at least 2 weeks prior to administration of study drug at regulatory approved doses
    • Stable dose of methotrexate 7.5 mg to 25 mg/day once weekly for at least 6 weeks prior to administration of study drug (no changes in dosing regimen for 4 weeks prior to screening)
    • Stable dose of hydroxychloroquine either monotherapy or in combination with methotrexate 8 weeks prior to administration of study drug
  9. Is a non-pregnant, non-lactating female who is postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months natural spontaneous amenorrhea

  10. If female of childbearing potential, must agree to use one of the following acceptable birth control methods:

    • Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to screening, hysterectomy, or bilateral oophorectomy);
    • Intrauterine device (IUD) in place for at least 3 months prior to first dose of study drug;
    • Abstinence (not having sexual intercourse);
    • Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion;
    • Stable hormonal contraceptive for at least 3 months prior to study and through study completion
  11. If female of childbearing potential, has a negative serum hCG pregnancy test at screening
  12. Is able to swallow whole tablets of orally administered medication
  13. Is able to understand and provide signed informed consent.

Exclusion Criteria:

  1. Has been diagnosed with any other inflammatory arthritis (eg, psoriatic arthritis)
  2. Has a secondary type of arthritis (eg, osteoarthritis) that would interfere with study evaluations

  3. Has taken the following drugs within the timeframe specified below:

    • Infliximab, etanercept, adalimumab, abatacept, or other biological therapies (except rituximab) - Within 12 weeks prior to the administration of study drug;
    • Rituximab - Within 12 months prior to the administration of study drug;
    • Disease-modifying antirheumatic drugs (DMARDs) or other anti-rheumatic therapies not specified above including but not limited to: sulfasalazine, gold, leflunomide, penicillamine, dapsone, azathioprine, 6-mercaptopurine, chlorambucil, cyclophosphamide, cyclosporin, mycophenolate mofetil - Within 12 weeks prior to the administration of study drug;
    • Any steroids (glucocorticoids); glucocorticoids must be discontinued for at least 4 weeks prior to administration of study drug. Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to administration of study drug.
    • Note: Use of probiotics is allowed and is NOT an exclusion criterion.
  4. Has a uncontrolled symptoms of fibromyalgia with sufficient symptoms requiring treatment (NOTE: patients on a stable dose of treatment for symptoms of fibromyalgia ≥ 4 weeks will be allowed in the study.)
  5. Has a history of allergic reaction to tetracycline or other related drugs
  6. Had major surgery or trauma within 28 days prior to screening
  7. Is concurrently using minocycline or doxycycline (washout of 4 weeks required before the administration of study drug)
  8. Patients who are on chronic antibiotics or who are on antibiotics for GI infections (such as Clostridium difficile)
  9. Has clinically significant ECG abnormalities
  10. Has any clinically significant abnormal laboratory test results found during medical screening including: AST or ALT > 2 x upper limit of normal or serum creatinine > 2.0 mg/dL
  11. Has clinically significant history or presence of any gastrointestinal pathology (eg, chronic diarrhea, inflammatory bowel disease, acute diverticulitis), irritable bowel syndrome, unresolved gastrointestinal symptoms (eg. diarrhea, vomiting, symptoms of acute diverticulitis), liver or kidney disease, gastric bypass, gastric stapling, use of Lap-Band®, or other conditions known to or which might interfere with the absorption, distribution, metabolism, or excretion of the drug
  12. Has any historical or active neurological, endocrine, cardiovascular, pulmonary, hematological, psychiatric, or metabolic disease that is considered clinically significant by the Investigator
  13. Has known history of HIV, hepatitis B or C (patients that have positive hepatitis B serology due to prior vaccination will be allowed in the study)
  14. Has an active malignancy of any type or history of malignancy. Patients who have a history of a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma (ie. non melanoma skin cancer)and/or localized carcinoma in situ of the cervix are eligible. Patients with a history of other malignancies that have been treated and who have no evidence of recurrence for at least 5 years before study enrollment are also eligible.
  15. Has difficulty swallowing tablets
  16. Is ACR Functional Class IV (limited ability to perform usual self-care, vocational, and avocational activities)
  17. Has known or suspected pregnancy, planned pregnancy, or lactation (for female patients)
  18. Has clinically significant mental illness (to be determined by the Investigator)
  19. Has a history in the last 2 years or current evidence of abuse of illicit drugs, prescription medications, or alcohol that, in the opinion of the Investigator, would interfere with adherence to study requirements. Has exposure to any investigational agent within 30 days prior to study entry.
  20. Was previously enrolled in this study
  21. Has recent history of bacterial intestinal tract infection (gastroenteritis, colitis, diverticulitis, appendicitis)
  22. Has a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo
Arzneimittel: Matching Placebo
Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
Experimental: MRC375 75 mg
MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
Arzneimittel: MRC375
MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
Experimental: MRC375 150mg
MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
Arzneimittel: MRC375 150mg
MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Efficacy evaluated of both doses of MRC375 compared to placebo after 24 weeks of treatment as measured by the rate of achievement of 20% improvement in ACR criteria
Zeitfenster: 24 weeks
evaluate efficacy of both doses of MRC375 compared to placebo after 24 weeks of treatment, as measured by a rate of achievement of 20% improvement in American College of Rheumatology (ACR) criteria (ACR20) at Week 24
24 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Safety and tolerability of both doses of MRC375
Zeitfenster: 24 weeks
evaluate the safety and tolerability of both doses of MRC375 tablets
24 weeks
Compare the Efficacy of two doses of MRC375 when compared to a placebo for the change from baseline screening in each of the individual ACR components measuring RA after 24 weeks of treatment
Zeitfenster: 24 weeks
compare the efficacy of 2 doses of MRC375 tablets (75 mg tid and 150 mg tid) when compared to placebo for the change from baseline screening in each of the individual ACR components measuring rheumatoid arthritis (RA) after 24 weeks of treatment.
24 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Molecular Research Center, Inc.

Mitarbeiter

Harrison Clinical Research
Camargo Pharmaceutical Services
Clin Data Services
BARC Global Central Laboratory
Bilcare Global Clinical Supplies

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. November 2011

Primärer Abschluss (Voraussichtlich)

1. Juli 2014

Studienabschluss (Voraussichtlich)

1. Juli 2014

Studienanmeldedaten

Zuerst eingereicht

2. August 2011

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. August 2011

Zuerst gepostet (Schätzen)

3. August 2011

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

12. Mai 2014

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. Mai 2014

Zuletzt verifiziert

1. Mai 2014

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • MRC2011-001

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Rheumatoide Arthritis

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in New Zealand

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren